Preclinical research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Chairman's Brands is a privately held corporation dedicated to the franchising, development, and marketing of quick-service restaurants. Until 2006, its main operation was Coffee Time with operations in Canada, Greece, Poland, China, Qatar and Saudi Arabia. The chain's first store was opened in 1982 by Tom Michalopoulos in Bolton, Ontario. In October 2006, the company doubled in size, when it purchased the Afton Food Group, a company whose assets included Robin's Donuts, 241 Pizza and Mrs. Powell's Cinnamon Buns. The company also operates Eggsmart, and The Friendly Greek. In all, Chairman's Brands operates more than 500 stores across Canada under its seven brands. As of November 15, 2016, they operated eight brands with over 440 locations in five countries. The brands were 241 Pizza, Coffee Time, Eggsmart, Mia Fresco, New Orleans Pizza, Robin's, and The Friendly Greek.
==== Disadvantages of Microbubbles for Drug Delivery ==== Microbubbles do not extravasate easily due to their large size, and hence their effects are relegated to the vasculature. Nanodroplets, perfluorocarbon liquid droplets surrounded by a lipid shell that vaporize due to an ultrasound pulse, offer a small diameter to promote extravasation and afford an alternative to microbubbles. Microbubbles have short half-lives on the order of minutes in circulation, which limits the treatment time. Microbubbles are filtered by the liver and spleen, and any drug conjugation would then also potentially pose a toxicity threat to these organs, should the microbubbles not have already released their cargo. Drug conjugations to microbubbles are complicated for translation, and these formulations would be difficult to scale up for widespread use. There can be a small amount hemorrhage into brain tissue when microbubbles are used to disrupt the blood brain barrier, though this is thought to be reversible.
=== Entomotherapy: Nutritional and Medicinal Benefits === Insects have played a significant role in traditional and modern medicine across various cultures. The Food and Agriculture Organization (FAO) Edible Insects Report highlights the nutritional and therapeutic potential of insects, they have high protein content, essential fatty acids, and bioactive compounds. Some traditional healing practices incorporate insects as remedies for inflammatory conditions, infections, and gastrointestinal disorders. In China and other parts of Asia silkworm derived compounds have been used in traditional medicine to treat high blood pressure and atherosclerosis. Similarly termites and grasshoppers are utilized in African medicine for their perceived immune boosting effects.
=== Food fortification === Countries fortify foods with nutrients to address known deficiencies. As of 2020, 54 countries required food fortification of wheat flour with nicotinic acid or nicotinamide; 14 also mandate fortification of maize flour, and 6 mandate fortification of rice. From country to country, niacin fortification ranges from 1.3 to 6.0 mg/100 g.
Sources: en.wikipedia.org
Isomerases Rearrangements in which a hydrogen atom is directly transferred between two adjacent atoms with concomitant exchange of the second substituent, X, which may be a carbon atom with substituents, an oxygen atom of an alcohol, or an amine. These use the AdoB12 (adenosylcobalamin) form of the vitamin. Methyltransferases Methyl (–CH3) group transfers between two molecules. These use the MeB12 (methylcobalamin) form of the vitamin. Dehalogenases Some species of anaerobic bacteria synthesize B12-dependent dehalogenases, which have potential commercial applications for degrading chlorinated pollutants. The microorganisms may either be capable of de novo corrinoid biosynthesis or are dependent on exogenous vitamin B12. In humans, two major coenzyme B12-dependent enzyme families corresponding to the first two reaction types, are known. These are typified by the following two enzymes:
The kidneys have an important role in maintaining health. When the person is healthy, the kidneys maintain the body's internal equilibrium of water and minerals (sodium, potassium, chloride, calcium, phosphorus, magnesium, sulphate). The acidic metabolism end-products that the body cannot get rid of via respiration are also excreted through the kidneys. The kidneys also function as a part of the endocrine system, producing erythropoietin, calcitriol and renin. Erythropoietin is involved in the production of red blood cells and calcitriol plays a role in bone formation. Dialysis is an imperfect treatment to replace kidney function because it does not correct the compromised endocrine functions of the kidney. Dialysis treatments replace some of these functions through diffusion (waste removal) and ultrafiltration (fluid removal). Dialysis uses highly purified (also known as "ultrapure") water.
=== Radiology === Radiologically, the main feature required for a confident diagnosis of UIP is honeycomb change in the periphery and the lower portions (bases) of the lungs. On high-resolution computed tomography (HRCT), the following categories, depending on imaging findings, have been recommended by a collaborative effort by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society:
Sources: en.wikipedia.org
== Honors == Robert M. Scarborough Award for Excellence in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2009) Inducted as an American Chemical Society Fellow (2011) Alfred Burger Award in Medicinal Chemistry, American Chemical Society (2014) Inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame (2014) Edward E. Smissman Award in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2019) IUPAC–Richter Prize in Medicinal Chemistry (2020)
== Possible Complications == As described above, when a fistulectomy is performed to remove an anorectal fistula tract that involves the anal sphincters, a common complication that may occur is fecal incontinence. The degree of incontinence can be measured using the Wexner score, which can allow surgeons to monitor the progression of incontinence post-operatively. As with other surgeries, fistulectomies may also pose other complications such as delayed wound healing and infection.
19 October – The SNP appoints Carol Beattie, a former chief executive of Stirling Council, as interim chief executive following the resignation of Murray Foote. 20 October – The UK government announces plans to appoint a minister to oversee the building of HS2, as well as confirming it will not reinstate the route's Birmingham to Manchester leg. The Sunday Times reports that Rushanara Ali has given up responsibility for managing building safety after survivors of the Grenfell tower fire called for her to stand down following an article that highlighted her attendance at the Franco-British Colloque, a conference that brings together senior politicians, civil servants and business leaders. 21 October – A Freedom of Information request reveals that Suella Braverman sent government documents to her private email account 127 times while she was Attorney General, potentially breaching the ministerial code. 22 October – The Welsh Government pays a £19m tax bill for the environment agency, Natural Resources Wales, following a HM Revenue and Customs investigation into how the agency hired specialist contractors. The UK signs what it has described as a "landmark defence agreement" with Germany. 23 October – Charles III and Camilla arrive in Samoa for a state visit, where the King will preside over the 2024 Commonwealth Heads of Government Meeting. The Senedd votes 26–19 to defeat a motion calling for a new law to allow assisted dying in England and Wales.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.